ACTH Stability on Whole Blood
NCT04266587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2026-02-10
Summary
ACTH is a peptide secreted by pituitary gland and plays an important role in regulating cortisol secretion. ACTH is determined in plasma by immunoassays using specific antibodies. Its determination is difficult because of instability in whole blood. Several factors which influence ACTH stability in blood before analysis have been identified: temperature, hemolysis, time to centrifugation and presence of protease inhibitors. Published results on ACTH whole blood stability seem contradictory.
The objective of this study is to evaluate the effect of aprotinin in 10 healthy volunteers. ACTH measurements will be performed on cobas e602 (Roche Diagnostics, Mannheim, Germany).
Conditions
- ACTH
Interventions
- BIOLOGICAL
-
Blood sampling
blood sampling is done on healthy volunteers
Sponsors & Collaborators
-
University Hospital, Rouen
lead OTHER
Principal Investigators
-
Francois FRAISSINET · University Hospital, Rouen
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-11-18
- Primary Completion
- 2021-11-18
- Completion
- 2021-11-18
Countries
- France
Study Locations
More Related Trials
-
Age-related Differences in Response to Pituitary Stimulation Tests
NCT04572139 ·Status: COMPLETED
-
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
NCT00851942 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers
NCT03752190 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism
NCT04833192 ·Status: UNKNOWN
-
Long Term Outcome Study in Patients With Pituitary Disorders
NCT03665064 ·Status: ACTIVE_NOT_RECRUITING
-
An Assessment of the Occurrence of Hormone Deficiency in Patients With Empty Sella
NCT04700020 ·Status: UNKNOWN ·Phase: NA
-
Acylated Ghrelin Response to Acute Exercise in Obesity
NCT00486161 ·Status: COMPLETED
-
Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity
NCT01028742 ·Status: COMPLETED
-
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
NCT04621565 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 ·Status: COMPLETED ·Phase: PHASE3
-
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing
NCT00324064 ·Status: COMPLETED ·Phase: NA
-
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
NCT00372697 ·Status: COMPLETED ·Phase: PHASE3
-
Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
NCT00139945 ·Status: COMPLETED ·Phase: NA
-
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
NCT01440686 ·Status: COMPLETED ·Phase: PHASE1
-
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
NCT06955286 ·Status: RECRUITING
-
Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure
NCT01576861 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnosing Adult Growth Hormone Deficiency
NCT03018886 ·Status: COMPLETED ·Phase: NA
-
Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet
NCT02049671 ·Status: UNKNOWN
-
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
NCT02558829 ·Status: COMPLETED ·Phase: PHASE3
-
Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion
NCT02655263 ·Status: COMPLETED ·Phase: NA
-
Growth Hormone Evaluation in the Elderly People
NCT02240043 ·Status: COMPLETED ·Phase: NA
-
Seoul National University Pituitary Disease Cohort Study
NCT03474601 ·Status: UNKNOWN
-
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363 ·Status: COMPLETED ·Phase: PHASE4
-
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
NCT06607666 ·Status: COMPLETED
-
Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy
NCT03708523 ·Status: UNKNOWN